- Home
- Cardiac Safety Services Market
Global Cardiac Safety Services Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-478 | No of pages: 277 | Format:
Global cardiac safety services market is projected to register a CAGR of 15.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029
Market Segmentation:
Global Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the global cardiac safety services market are:
Increase in the number of clinical trials being conducted
Increase in prevalence of cardiovascular diseases
Market Players:
The key market players for global cardiac safety services market are listed below:
Biotrial
Banook Group
Bioclinica
Certara L.P.
Celerion, Inc.
Laboratory Corporation of America Holdings
Medpace Holdings, Inc.
Ncardia AG
Richmond Pharmacology
PhysioStim
IQVIA
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 27 1.1 OBJECTIVES OF THE STUDY 27 1.2 MARKET DEFINITION 27 1.3 OVERVIEW OF GLOBAL CARDIAC SAFETY SERVICES MARKET 27 1.4 LIMITATIONS 28 1.5 MARKETS COVERED 29 2 MARKET SEGMENTATION 31 2.1 MARKETS COVERED 31 2.2 GEOGRAPHICAL SCOPE 32 2.3 YEARS CONSIDERED FOR THE STUDY 33 2.4 CURRENCY AND PRICING 33 2.5 DBMR TRIPOD DATA VALIDATION MODEL 34 2.6 MULTIVARIATE MODELLING 37 2.7 SERVICES LIFELINE CURVE 37 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38 2.9 DBMR MARKET POSITION GRID 39 2.10 MARKET END USER GRID 41 2.11 VENDOR SHARE ANALYSIS 42 2.12 SECONDARY SOURCES 43 2.13 ASSUMPTIONS 43 3 EXECUTIVE SUMMARY 44 4 PREMIUM INSIGHTS 47 4.1 PORTERS FIVE FORCES 48 4.2 PESTEL ANALYSIS 49 5 EPIDEMIOLOGY 50 5.1 INCIDENCE OF ALL BY GENDER 50 5.2 TREATMENT RATE 51 5.3 MORTALITY RATE 51 5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 52 6 INDUSTRY INSIGHT 53 6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 53 6.2 PATENT ANALYSIS 54 6.3 PATENT FLOW DIAGRAM 55 6.4 KEY PATIENT ENROLLMENT STRATEGIES 55 6.5 PRICING STRATEGY 58 7 GLOBAL CARDIAC SAFETY SERVICES MARKET: REGULATIONS 59 8 MARKET OVERVIEW 62 8.1 DRIVERS 64 8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 64 8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 64 8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 65 8.1.4 INCREASE IN R&D ACTIVITIES 65 8.2 RESTRAINTS 66 8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 66 8.2.2 STRICT REGULATORY 66 8.3 OPPORTUNITIES: 67 8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 67 8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 68 8.4 CHALLENGES 68 8.4.1 TIME-CONSUMING PROCEDURE 68 8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 69 9 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY SERVICES 70 9.1 OVERVIEW 71 9.2 ECG/HOLTER MEASUREMENTS 75 9.3 BLOOD PRESSURE MEASUREMENTS 75 9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 76 9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 77 9.4.1.1 1 CONCENTRATIONS 77 9.4.1.2 4 CONCENTRATIONS 77 9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 78 9.4.2.1 3 CONCENTRATIONS 78 9.4.2.2 5 CONCENTRATIONS 78 9.4.3 IN VITRO HERG ASSAY 78 9.4.4 OTHERS 78 9.5 CARDIOVASCULAR IMAGING 78 9.6 REAL TIME TELEMETRY MONITORING 79 9.7 CENTRAL OVER-READ OF ECGS 80 9.8 NON-INVASIVE CARDIAC IMAGING 80 9.9 PHYSIOLOGIC STRESS TESTING 81 9.10 THOROUGH QT STUDIES 82 9.11 TQT AND EXPOSURE RESPONSE MODELLING 82 9.12 PLATELET AGGREGATION 83 9.13 OTHERS 84 10 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY PHASE 85 10.1 OVERVIEW 86 10.2 PHASE I 89 10.3 PHASE II 89 10.4 PHASE III 90 11 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY TYPE 91 11.1 OVERVIEW 92 11.2 INTEGRATED SERVICES 95 11.3 STANDALONE SERVICES 96 12 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY END USER 97 12.1 OVERVIEW 98 12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 101 12.3 CONTRACT RESEARCH ORGANIZATIONS 101 12.4 ACADEMIC AND RESEARCH INSTITUTE 102 13 GLOBAL CARDIAC SAFETY SERVICES MARKET, BY REGION 103 13.1 OVERVIEW 104 13.2 NORTH AMERICA 109 13.2.1 U.S. 117 13.2.2 CANADA 120 13.2.3 MEXICO 123 13.3 EUROPE 126 13.3.1 GERMANY 134 13.3.2 FRANCE 137 13.3.3 U.K. 140 13.3.4 ITALY 143 13.3.5 SPAIN 146 13.3.6 TURKEY 149 13.3.7 RUSSIA 152 13.3.8 NETHERLANDS 155 13.3.9 SWITZERLAND 158 13.3.10 BELGIUM 161 13.3.11 REST OF EUROPE 164 13.4 ASIA-PACIFIC 165 13.4.1 CHINA 173 13.4.2 JAPAN 176 13.4.3 SOUTH KOREA 179 13.4.4 INDIA 182 13.4.5 AUSTRALIA 185 13.4.6 SINGAPORE 188 13.4.7 THAILAND 191 13.4.8 MALAYSIA 194 13.4.9 INDONESIA 197 13.4.10 PHILIPPINES 200 13.4.11 REST OF ASIA-PACIFIC 203 13.5 SOUTH AMERICA 204 13.5.1 BRAZIL 212 13.5.2 ARGENTINA 215 13.5.3 REST OF SOUTH AMERICA 218 13.6 MIDDLE EAST AND AFRICA 219 13.6.1 SOUTH AFRICA 227 13.6.2 SAUDI ARABIA 230 13.6.3 U.A.E. 233 13.6.4 ISRAEL 236 13.6.5 EGYPT 239 13.6.6 REST OF MIDDLE EAST AND AFRICA 242 14 GLOBAL CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 243 14.1 COMPANY SHARE ANALYSIS: GLOBAL 243 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 244 14.3 COMPANY SHARE ANALYSIS: EUROPE 245 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 246 15 COMPANY PROFILE 247 15.1 EUROFINS SCIENTIFIC 247 15.1.1 COMPANY SNAPSHOT 247 15.1.2 REVENUE ANALYSIS 248 15.1.3 COMPANY SHARE ANALYSIS 248 15.1.4 PRODUCT PORTFOLIO 248 15.1.5 RECENT DEVELOPMENTS 249 15.1.5.1 AGREEMENTS 249 15.1.5.2 ACQUISITION 249 15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 250 15.2.1 COMPANY SNAPSHOT 250 15.2.2 REVENUE ANALYSIS 250 15.2.3 COMPANY SHARE ANALYSIS 251 15.2.4 PRODUCT PORTFOLIO 251 15.2.5 RECENT DEVELOPMENT 251 15.2.5.1 INVESTMENT 251 15.3 KONINKLIJKE PHILIPS N.V. 252 15.3.1 COMPANY SNAPSHOT 252 15.3.2 REVENUE ANALYSIS 252 15.3.3 COMPANY SHARE ANALYSIS 253 15.3.4 PRODUCT PORTFOLIO 253 15.3.5 RECENT DEVELOPMENT 253 15.3.5.1 ACQUISITION 253 15.4 IQVIA 254 15.4.1 COMPANY SNAPSHOT 254 15.4.2 REVENUE ANALYSIS 254 15.4.3 COMPANY SHARE ANALYSIS 255 15.4.4 PRODUCT PORTFOLIO 255 15.4.5 RECENT DEVELOPMENTS 255 15.4.5.1 ACQUISITION 255 15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 256 15.5.1 COMPANY SNAPSHOT 256 15.5.2 REVENUE ANALYSIS 256 15.5.3 COMPANY SHARE ANALYSIS 257 15.5.4 PRODUCT PORTFOLIO 257 15.5.5 RECENT DEVELOPMENTS 257 15.5.5.1 NEW LABORATORY 257 15.5.5.2 ACQUISITION 257 15.6 BANOOK 258 15.6.1 COMPANY SNAPSHOT 258 15.6.2 PRODUCT PORTFOLIO 258 15.6.3 RECENT DEVELOPMENT 258 15.6.3.1 AGREEMENT 258 15.7 BIOTRIAL 259 15.7.1 COMPANY SNAPSHOT 259 15.7.2 PRODUCT PORTFOLIO 259 15.7.3 RECENT DEVELOPMENT 259 15.7.3.1 NEW CENTER OPENING 259 15.8 CELERION 260 15.8.1 COMPANY SNAPSHOT 260 15.8.2 PRODUCT PORTFOLIO 260 15.8.3 RECENT DEVELOPMENT 260 15.8.3.1 NEW CENTER OPENING 260 15.9 CERTARA 261 15.9.1 COMPANY SNAPSHOT 261 15.9.2 REVENUE ANALYSIS 261 15.9.3 PRODUCT PORTFOLIO 262 15.9.4 RECENT DEVELOPMENTS 262 15.9.4.1 CONTRACT 262 15.9.4.2 ACQUISITION 262 15.10 CLARIO 263 15.10.1 COMPANY SNAPSHOT 263 15.10.2 PRODUCT PORTFOLIO 263 15.10.3 RECENT DEVELOPMENT 263 15.10.3.1 PRODUCT EXPANSION 263 15.11 MEDPACE 264 15.11.1 COMPANY SNAPSHOT 264 15.11.2 REVENUE ANALYSIS 264 15.11.3 PRODUCT PORTFOLIO 265 15.11.4 RECENT DEVELOPMENTS 265 15.11.4.1 ACQUISITION 265 15.12 NCARDIA 266 15.12.1 COMPANY SNAPSHOT 266 15.12.2 PRODUCT PORTFOLIO 266 15.12.3 RECENT DEVELOPMENT 266 15.12.3.1 PARTNERSHIP 266 15.13 NEXEL CO., LTD 267 15.13.1 COMPANY SNAPSHOT 267 15.13.2 PRODUCT PORTFOLIO 267 15.13.3 RECENT DEVELOPMENTS 267 15.13.3.1 JOINT VENTURE 267 15.13.3.2 PARTNERSHIP 268 15.14 PHYSIOSTIM 269 15.14.1 COMPANY SNAPSHOT 269 15.14.2 PRODUCT PORTFOLIO 269 15.14.3 RECENT DEVELOPMENT 269 15.14.3.1 PARTNERSHIP 269 15.15 RICHMOND PHARMACOLOGY 270 15.15.1 COMPANY SNAPSHOT 270 15.15.2 PRODUCT PORTFOLIO 270 15.15.3 RECENT DEVELOPMENT 270 15.15.3.1 EVENT 270 15.16 SGS SA 271 15.16.1 COMPANY SNAPSHOT 271 15.16.2 REVENUE ANALYSIS 271 15.16.3 PRODUCT PORTFOLIO 272 15.16.4 RECENT DEVELOPMENT 272 15.16.4.1 ACQUISITION 272 15.17 SHANGHAI MEDICILON INC. 273 15.17.1 COMPANY SNAPSHOT 273 15.17.2 PRODUCT PORTFOLIO 273 15.17.3 RECENT DEVELOPMENTS 273 15.17.3.1 PARTNERSHIP 273 15.17.3.2 PARTNERSHIP 274 16 QUESTIONNAIRE 275 17 RELATED REPORTS 277Segmentation
Short Description Global Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029 Market Definition: Cardiac safety services generally help support and design clinical trials and other research needed to monitor heart safety. The demand for cardiac safety services market has been increased in both developed well as in developing countries and the reason behind this is the increasing number of clinical trials and product launch. The cardiac safety services market is growing due to introduction of innovative products, increasing in technological products and rising disposable income. The market will grow in forecasted period due to exploration of emerging markets, strategic initiatives by market players, increasing healthcare expenditure. Market Segmentation: Global cardiac safety services market is categorized into four notable segment which is services, type, phase and end user. On the basis of services, the cardiac safety services market is segmented into ECG/Holter measurements, blood pressure measurements, in vitro cardiac safety assessment services, cardiovascular imaging, real-time telemetry monitoring, central over-read of ECGS, non-invasive cardiac imaging, physiologic stress testing, thorough QT studies, TQT and exposure response modeling, platelet aggregation and other services. On the basis of phases, the cardiac safety services market is segmented into phase 1, phase 2 and phase 3. In 2022, phase 1 is expected to dominate the global cardiac safety services market with the increasing new drug development and rising strategic initiatives by major market players. On the basis of type, the cardiac safety services market is segmented into integrated services and standalone services. In 2022, integrated services is expected to dominate the global cardiac safety services market with the increasing advanced technology and rising healthcare expenditure. On the basis of end user, the cardiac safety services market is segmented pharmaceuticals & biopharmaceuticals companies, contract research organizations and academic and research institute. In 2022, hospital is expected to dominate the global cardiac safety services market with the increasing number of patients and surgeries. Market Players The key market players for global cardiac safety services market are listed below: Koninklijke Philips N.V. Laboratory Corporation of America Holdings IQVIA Medpace Ncardia Certara Eurofins Scientific SGS SA Banook Celerion Biotrial NEXEL Co., Ltd Richmond Pharmacology PhysioStim Shanghai Medicilon Inc Clario PPD IncMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.